Important Elements for the Diagnosis of Drug-Induced Liver Injury

Galan, 2005, The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center, J Clin Gastroenterol, 39, 64 Lee, 2003, Acute liver failure in the United States, Semin Liver Dis, 23, 217, 10.1055/s-2003-42641 Chalasani, 2008, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States, Gastroenterology, 135, 1924, 10.1053/j.gastro.2008.09.011 Venulet, 1985, Informativity of adverse reactions data in medical publications, Drug Inf J, 19, 357, 10.1177/009286158501900327 Kelly, 2003, The quality of published adverse drug event reports, Ann Pharmacother, 37, 1774, 10.1345/aph.1D202 Fontana, 2009, Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 Benichou, 1990, Criteria of drug-induced liver disorders, J Hepatol, 11, 272, 10.1016/0168-8278(90)90124-A Danan, 1993, Causality assessment of adverse reactions to drugs—I, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 Cundiff, 2007, Amoxicillin-clavulanic acid-induced hepatitis, Am J Otolaryngol, 28, 28, 10.1016/j.amjoto.2006.06.007 Fontana, 2005, Acute liver failure due to amoxicillin and amoxicillin/clavulanate, Dig Dis Sci, 50, 1785, 10.1007/s10620-005-2938-5 Andrade, 2001, Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid, Dig Dis Sci, 46, 1416, 10.1023/A:1010627518254 Chawla, 2000, Rapidly progressive cholestasis: an unusual reaction to amoxicillin/clavulanic acid therapy in a child, J Pediatr, 136, 121, 10.1016/S0022-3476(00)90064-7 Nathani, 1998, An unusual case of amoxicillin/clavulanic acid-related hepatotoxicity, Am J Gastroenterol, 93, 1363, 10.1111/j.1572-0241.1998.00418.x Ryley, 1995, Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin), J Hepatol, 23, 278 Hautekeete, 1995, Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations, J Hepatol, 22, 71, 10.1016/0168-8278(95)80262-2 Habior, 1994, Hepatocellular-cholestatic liver injury due to amoxycillin-clavulanic acid combination, Clin Investig, 72, 616, 10.1007/BF00227455 Larrey, 1992, Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases, Gut, 33, 368, 10.1136/gut.33.3.368 Julie, 2008, Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone, Diabetologia, 51, 10.1007/s00125-008-1133-6 Caldwell, 2001, Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin, Dig Dis Sci, 46, 376, 10.1023/A:1005505827545 Menon, 2001, Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus, Am J Gastroenterol, 96, 1631, 10.1111/j.1572-0241.2001.03809.x Chaudhary, 2001, Case of the month, J Ark Med Soc, 98, 16 Prendergast, 2000, Troglitazone-associated hepatotoxicity treated successfully with steroids, Ann Intern Med, 133, 751, 10.7326/0003-4819-133-9-200011070-00034 Schiano, 2000, Severe but reversible hepatitis induced by troglitazone, Dig Dis Sci, 45, 1039, 10.1023/A:1005510132625 Li, 2000, Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings, J Diabetes Complications, 14, 175, 10.1016/S1056-8727(00)00076-3 Jagannath, 2000, Rapid-onset subfulminant liver failure associated with troglitazone, Ann Intern Med, 132, 677, 10.7326/0003-4819-132-8-200004180-00021 Kohlroser, 2000, Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration, Am J Gastroenterol, 95, 272, 10.1111/j.1572-0241.2000.01707.x Murphy, 2000, Troglitazone-induced fulminant hepatic failure, Dig Dis Sci, 45, 549, 10.1023/A:1005405526283 Fukano, 2000, Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination, Hum Pathol, 31, 250, 10.1016/S0046-8177(00)80229-4 Malik, 2000, Hepatic injury due to troglitazone, Dig Dis Sci, 45, 210, 10.1023/A:1005450519498 Bell, 2000, Late-onset troglitazone-induced hepatic dysfunction, Diabetes Care, 23, 128, 10.2337/diacare.23.1.128 Herrine, 1999, Severe hepatotoxicity associated with troglitazone, Ann Intern Med, 130, 163, 10.7326/0003-4819-130-2-199901190-00021 Vella, 1998, Fatal hepatotoxicity associated with troglitazone, Ann Intern Med, 129, 1080, 10.7326/0003-4819-129-12-199812150-00032 Shibuya, 1998, An autopsy case of troglitazone-induced fulminant hepatitis, Diabetes Care, 21, 2140, 10.2337/diacare.21.12.2140 Neuschwander-Tetri, 1998, Troglitazone-induced hepatic failure leading to liver transplantation, Ann Intern Med, 129, 38, 10.7326/0003-4819-129-1-199807010-00009 Gitlin, 1998, Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone, Ann Intern Med, 129, 36, 10.7326/0003-4819-129-1-199807010-00008 El-Naggar, 2008, Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma, Ann Pharmacother, 42, 713, 10.1345/aph.1K543 Su, 2006, Liver failure in a patient receiving rosiglitazone therapy, Diabet Med, 23, 105, 10.1111/j.1464-5491.2006.01791.x Menees, 2005, Hepatic injury in a patient taking rosiglitazone, J Clin Gastroenterol, 39, 638, 10.1097/01.mcg.0000170768.59696.16 Dhawan, 2002, Rosiglitazone-induced granulomatous hepatitis, J Clin Gastroenterol, 34, 582, 10.1097/00004836-200205000-00021 Bonkovsky, 2002, Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone, Dig Dis Sci, 47, 1632, 10.1023/A:1015895925374 Gouda, 2001, Liver failure in a patient treated with long-term rosiglitazone therapy, Am J Med, 111, 584, 10.1016/S0002-9343(01)00926-3 Ravinuthala, 2000, Rosiglitazone toxicity, Ann Intern Med, 133, 658, 10.7326/0003-4819-133-8-200010170-00025 Hachey, 2000, Isolated elevation of alkaline phosphatase level associated with rosiglitazone, Ann Intern Med, 133, 752, 10.7326/0003-4819-133-9-200011070-00035 Forman, 2000, Hepatic failure in a patient taking rosiglitazone, Ann Intern Med, 132, 118, 10.7326/0003-4819-132-2-200001180-00005 Al-Salman, 2000, Hepatocellular injury in a patient receiving rosiglitazone, Ann Intern Med, 132, 121, 10.7326/0003-4819-132-2-200001180-00006 Martínez Odriozola, 2007, [A new case: pioglitazone hepatotoxicity], Med Clin (Barc), 129, 158, 10.1157/13107492 Arotçarena, 2004, [Pioglitazone-induced acute severe hepatitis], Gastroenterol Clin Biol, 28, 610, 10.1016/S0399-8320(04)95021-X Marcy, 2004, Second-generation thiazolidinediones and hepatotoxicity, Ann Pharmacother, 38, 1419, 10.1345/aph.1E072 Pinto, 2002, Severe but reversible cholestatic liver injury after pioglitazone therapy, Ann Intern Med, 137, 857, 10.7326/0003-4819-137-10-200211190-00023 Nagasaka, 2002, Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success, Diabet Med, 19, 344, 10.1046/j.1464-5491.2002.00712_4.x May, 2002, Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy, Ann Intern Med, 136, 449, 10.7326/0003-4819-136-6-200203190-00008 Chase, 2002, Pioglitazone-associated fulminant hepatic failure, Am J Gastroenterol, 97, 502, 10.1111/j.1572-0241.2002.05516.x Maeda, 2001, Hepatocellular injury in a patient receiving pioglitazone, Ann Intern Med, 135, 306, 10.7326/0003-4819-135-4-200108210-00029 Soy, 2002, Vasculitis induced by zafirlukast therapy, Clin Rheumatol, 21, 328, 10.1007/s100670200086 Torres, 2001, Severe liver injury, Ann Intern Med, 135, 550, 10.7326/0003-4819-135-7-200110020-00019 Moles, 2001, Acute hepatocellular injury associated with zafirlukast [letter], J Hepatol, 35, 541, 10.1016/S0168-8278(01)00124-6 Danese, 2001, Severe liver injury associated with zafirlukast [letter], Ann Intern Med, 135, 930, 10.7326/0003-4819-135-10-200111200-00023 Actis, 2001, Zafirlukast-related hepatitis: report of a further case [letter], J Hepatol, 35, 539, 10.1016/S0168-8278(01)00123-4 Reinus, 2000, Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast, Ann Intern Med, 133, 964, 10.7326/0003-4819-133-12-200012190-00011 Actis, 2007, Fatal liver failure following food supplements during chronic treatment with montelukast, Dig Liver Dis, 39, 953, 10.1016/j.dld.2006.10.002 Goldstein, 2004, Montelukast-induced hepatitis, Ann Intern Med, 140, 586, 10.7326/0003-4819-140-7-200404060-00042 Sass, 2003, A case of montelukast-induced hepatotoxicity, Am J Gastroenterol, 98, 704, 10.1111/j.1572-0241.2003.07316.x Russmann, 2003, Acute hepatitis associated with montelukast, J Hepatol, 38, 694, 10.1016/S0168-8278(03)00085-0